Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
December 03, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
December 02, 2025 08:50 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
November 11, 2025 07:00 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics to Present at Oxford Global’s Cell 2025

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
November 10, 2025 08:35 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead...
November 06, 2025 09:15 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the...
October 01, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
September 29, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
September 17, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
September 10, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...